HUTCHMED Announces Savolitinib sNDA Accepted in China for Tr

— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients —

Related Keywords

Hong Kong , China , United States , Poland , Shanghai , Polish , American , Atholl Tweedie , Zhou Yi , Ben Atwell , Linkedin , Single Institution Study , American Cancer Society , Stock Exchange Of Hong Kong , Nasdaq , China National Medical Products Administration , Exchange Commission , European Lung Cancer Congress On , European Lung Cancer Congress , National Reimbursement Drug List , World Health Organization , Astrazeneca , China Limited , International Agency For Research On Cancer , New Drug Application , Lung Cancer , Securities Litigation Reform Act , Stock Exchange , Hong Kong Limited , International Agency , Accessed November , Clinical Oncology Provisional Opinion , Epidermal Growth Factor Receptor , Mutation Testing , Kinase Inhibitor , Histological Samples , Small Cell Lung Cancer , Systematic Review , Intj Clin Exp , Mutated Advanced Non Small Cell Lung , Positive Lung , Clinical Oncology , Region ,